Latest Period
Q1 2026
Security Snapshot
APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 Institutional Ownership
CUSIP: 03753UAB2
13F Institutional Holders and Ownership History from Q3 2020 to Q2 2026
Institutions Reporting
7
Principal
$93,840,000
Price (% of par)
106.0%
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Debt / NOTE 3.500% 9/1
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F principal
- $93,840,000
- Total 13F market value
- $99,256,294
- Principal change
- $0
- Market value change
- +$28,101
- Number of holders
- 7
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- 03753UAB2 - APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 is tracked under CUSIP 03753UAB2.
- 7 institutions reported positions in Q1 2026.
- Schedule 13D/13G significant owner rows are not currently available.
Change
- Holder count moved from 7 to 0 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $99,256,294 to $0.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 7 institutions filings for Q1 2026.
Security key
03753UAB2
Latest holder period
Q1 2026
13F holders
7
13D/G owners
0
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03753UAB2:
As of 31 Mar 2026, 7 institutional investors reported holding $93,840,000 in principal (par value) of APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
24
Latest
Q1 2026
Rows shown
1-24 of 24
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | $0 | $0 | -$6,300 | 0 | |
| 2026 Q1 | $93,840,000 | $99,256,294 | +$28,101 | 106.0% | 7 |
| 2025 Q4 | $93,840,000 | $96,599,364 | 103.21% | 8 | |
| 2025 Q3 | $93,840,000 | $96,878,614 | +$571 | 102.94% | 8 |
| 2025 Q2 | $93,840,000 | $93,783,959 | -$35,697 | 99.67% | 8 |
| 2025 Q1 | $93,840,000 | $98,123,513 | -$3,650 | 104.45% | 9 |
| 2024 Q4 | $93,840,000 | $108,788,109 | -$12,067,908 | 115.78% | 9 |
| 2024 Q3 | $105,678,000 | $116,622,644 | -$335,591 | 109.6% | 9 |
| 2024 Q2 | $105,978,000 | $134,815,813 | +$14,470,332 | 127.96% | 9 |
| 2024 Q1 | $92,385,000 | $150,593,192 | -$2,230,226 | 163.14% | 13 |
| 2023 Q4 | $93,849,769 | $152,855,058 | +$2,170,617 | 163.36% | 11 |
| 2023 Q3 | $93,849,454 | $118,114,618 | -$56,841,055 | 125.53% | 12 |
| 2023 Q2 | $105,572,796 | $252,922,195 | +$25,158,974 | 239.52% | 15 |
| 2023 Q1 | $106,821,000 | $198,647,115 | +$15,253,734 | 186.11% | 10 |
| 2022 Q4 | $98,703,000 | $151,622,681 | +$1,877,380 | 153.88% | 12 |
| 2022 Q3 | $93,864,000 | $181,014,357 | -$78,666,463 | 194.85% | 12 |
| 2022 Q2 | $138,949,000 | $205,684,098 | -$92,889,077 | 149.26% | 13 |
| 2022 Q1 | $199,820,000 | $315,544,975 | +$5,454,309 | 158.27% | 17 |
| 2021 Q4 | $197,907,000 | $299,084,574 | +$5,431,421 | 151.26% | 23 |
| 2021 Q3 | $197,218,000 | $242,364,333 | -$365,841,054 | 122.85% | 23 |
| 2021 Q2 | $401,095,000 | $746,370,187 | +$577,634,645 | 185.97% | 38 |
| 2021 Q1 | $96,675,000 | $135,757,022 | -$192,335,574 | 140.39% | 21 |
| 2020 Q4 | $211,550,000 | $356,794,918 | +$38,081,464 | 168.06% | 29 |
| 2020 Q3 | $215,022,000 | $232,250,866 | +$232,250,866 | 107.56% | 27 |